Sodium-Glucose Co-Transporter 2 Inhibition in Diabetes Treatment: Current Evidence and Future Perspectives

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|22|3647-3656

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.22, 2014-05, pp. : 3647-3656

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D   Wilding John PH  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

By Lamos Elizabeth M   Younk Lisa M   Davis Stephen N  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 6, 2014-06 ,pp. : 875-882

Informa Healthcare

Access to resources Recommend Favorite

Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth M  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 763-775

Informa Healthcare

Access to resources Recommend Favorite

Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’

By  

Current Pharmaceutical Design, Vol. 16, Iss. 34, 2010-11 ,pp. : 3830-3838

Bentham Science Publishers

Access to resources Recommend Favorite

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

By Washburn William N  

Expert Opinion on Therapeutic Patents, Vol. 19, Iss. 11, 2009-11 ,pp. : 1485-1499

Informa Healthcare

Access to resources Recommend Favorite